Paying users zone. Data is hidden behind 
.
Get 1-month access to Bristol-Myers Squibb Co. for $17.99, or
get full access to the entire website for at least 3 months from $49.99.
We accept:
This is a one-time payment. There is no automatic renewal.
Bristol-Myers Squibb Co. (BMY)
Analysis of Revenues
Advanced level
Accounting Policy on Revenue Recognition
Effective January 1, 2018, BMS adopted ASC 606 using the modified retrospective method.
Source: 10-K (filing date: 2019-02-25).
Revenues as Reported
Bristol-Myers Squibb Co., Income Statement, Revenues
US$ in millions
| 12 months ended | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| BioPharmaceuticals | |
|
|
|
|
||||||
| Revenues | |
|
|
|
|
Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).
| Item | Description | The company |
|---|---|---|
| Revenues | Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). | Bristol-Myers Squibb Co.’s revenues increased from 2016 to 2017 and from 2017 to 2018. |